Literature DB >> 28671350

von Willebrand factor and inflammation.

C Kawecki1,2,3, P J Lenting1, C V Denis1.   

Abstract

Von Willebrand factor (VWF) is a plasma glycoprotein best known for its crucial hemostatic role in serving as a molecular bridge linking platelets to subendothelial components following vascular injury. In addition, VWF functions as chaperone for coagulation factor VIII. In pathological settings, VWF is recognized as a risk factor for both arterial and venous thrombosis, as well as a molecular player that directly promotes the thrombotic process. Recent years have seen the emergence of the concept of immuno-thrombosis by which inflammatory cells participate in thrombotic processes. In return, reports about the involvement of hemostatic proteins or cells (such as platelets) in inflammatory responses have become increasingly common, emphasizing the intricate link between hemostasis and inflammation. However, evidence of a link between VWF and inflammation arose much earlier than these recent developments. At first, VWF was considered only as a marker of inflammation in various pathologies, due to its acute release by the activated endothelium. Later on, a more complex role of VWF in inflammation was uncovered, owing to its capacity to direct the biogenesis of specific endothelial organelles, the Weibel-Palade bodies that contain known inflammation players such as P-selectin. Finally, a more direct link between VWF and inflammation has become apparent with the discovery that VWF is able to recruit leukocytes, either via direct leukocyte binding or by recruiting platelets which in turn will attract leukocytes. This review will focus on these different aspects of the connection between VWF and inflammation, with particular emphasis on VWF-leukocyte interactions.
© 2017 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  Weibel-Palade bodies; endothelium; inflammation; leukocytes; von Willebrand factor

Mesh:

Substances:

Year:  2017        PMID: 28671350     DOI: 10.1111/jth.13696

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  61 in total

1.  The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing.

Authors:  Jun Ishihara; Ako Ishihara; Richard D Starke; Claire R Peghaire; Koval E Smith; Thomas A J McKinnon; Yoji Tabata; Koichi Sasaki; Michael J V White; Kazuto Fukunaga; Mike A Laffan; Matthias P Lutolf; Anna M Randi; Jeffrey A Hubbell
Journal:  Blood       Date:  2019-04-11       Impact factor: 22.113

2.  Recombinant human ADAMTS13 treatment and anti-NET strategies enhance skin allograft survival in mice.

Authors:  Siu Ling Wong; Jeremy Goverman; Caleb Staudinger; Denisa D Wagner
Journal:  Am J Transplant       Date:  2019-12-12       Impact factor: 8.086

3.  Complex Interaction of Platelets, von Willebrand Factor and Leukocytes, in Whole Blood at High Shear Rates Is Mediated by Platelet GPIIb/IIIa Receptor.

Authors:  Yu N Avtaeva; I S Mel'nikov; O S Saburova; K G Guriya; M C Osidak; C P Domogatsky; Z A Gabbasov
Journal:  Bull Exp Biol Med       Date:  2021-10-07       Impact factor: 0.804

4.  Hemocoagulative Modifications after Laparoscopic Surgery at Different Pneumoperitoneum Pressure Settings.

Authors:  Intagliata Eva; Vecchio Rosario; Saitta Cesare; Vizzini Clarissa; Lo Presti Federica; Cacciola Rossella Rosaria; Cacciola Emma; Vecchio Veronica
Journal:  Int J Surg Protoc       Date:  2022-06-14

5.  von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.

Authors:  Ferdows Atiq; Lisette M Schütte; Agnes E M Looijen; Johan Boender; Marjon H Cnossen; Jeroen Eikenboom; Moniek P M de Maat; Marieke J H A Kruip; Frank W G Leebeek
Journal:  Blood Adv       Date:  2019-12-23

Review 6.  Low VWF: insights into pathogenesis, diagnosis, and clinical management.

Authors:  James S O'Donnell
Journal:  Blood Adv       Date:  2020-07-14

7.  Histo-blood group A is a risk factor for severe COVID-19.

Authors:  Pedro M M Garibaldi; Luciana C Oliveira; Benedito A da Fonseca; Maria Auxiliadora-Martins; Carlos H Miranda; Carlos E L Almado; Dante M Langhi; Renato N Gilio; Leonardo C Palma; Bruno B M Gomes; Camila Bottura; Larissa C Barrientto; Camila D Donadel; Rodrigo T Calado; Gil C De Santis
Journal:  Transfus Med       Date:  2021-06-03       Impact factor: 2.057

Review 8.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

Review 9.  The potential roles of Von Willebrand factor and neutrophil extracellular traps in the natural history of hypertrophic and hypertensive cardiomyopathy.

Authors:  Richard C Becker; A Phillip Owens; Sakthivel Sadayappan
Journal:  Thromb Res       Date:  2020-05-07       Impact factor: 3.944

Review 10.  Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.

Authors:  Krishna Sriram; Paul A Insel
Journal:  Physiol Rev       Date:  2020-10-30       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.